There's so much information to digest in this report, but on first scan it looks great and importantly that there is no indication that COVID-19 has had any effect on the operations of the company. That is important for people to consider when viewing possible shutdowns etc as PAR will continue to truck on and its business will not be affected. So if any downswings do occur in the next couple of weeks, then you know the fundamentals haven't changed, just the market panic!
Interesting points from update I thought (which are definitely new and not "regurgitate")
- video to be released with the NFL results. That strikes me as the PAR team know the results are going to be amazing (and video already filmed), as why would you release a video of athletes walking around in pain? Not logical - so very likely that you're going to see some hall of famers unable to walk properly in the first shot, and then running laps and catching touchdowns in the second shot. Whilst that may seem trivial to some, I assume our American investors will love it to no end given it would play to their love of theatrics and the grand design of a miracle drug!
- teaming with Australian university to investigate safety and efficacy of iPPS in a viral induced respiratory disease. Anyone know of a viral respiratory disease atm? I like too how they have not spelt out COVID-19 to avoid being grouped into the same class as those companies who have attached investigations into COVID-19 on every announcement heading.
One thing I hope some of the more knowledgeable posters will provide guidance on is re the TGA Provisional Approval application. The timing guidelines seem to be met, positive feedback has been received, SAS data is soon to be received...therefore are we still "looking good" for potential provisional treatment under TGA? If so, what happens to Phase 3?
- Forums
- ASX - By Stock
- PAR
- Ann: NEW FINANCIAL YEAR UPDATE
Ann: NEW FINANCIAL YEAR UPDATE, page-20
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
24.0¢ |
Change
-0.005(2.04%) |
Mkt cap ! $83.98M |
Open | High | Low | Value | Volume |
25.0¢ | 25.5¢ | 24.0¢ | $202.2K | 814.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 181098 | 24.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
25.0¢ | 118621 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 181098 | 0.240 |
4 | 27745 | 0.235 |
1 | 25000 | 0.230 |
5 | 41756 | 0.225 |
7 | 59930 | 0.220 |
Price($) | Vol. | No. |
---|---|---|
0.250 | 74601 | 4 |
0.255 | 50000 | 1 |
0.260 | 21333 | 2 |
0.265 | 69367 | 4 |
0.270 | 53000 | 2 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online